Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma
-
- Ikeda Munehiro
- Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
-
- Tamada Takashi
- Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
-
- Takebayashi Risa
- Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
-
- Okuno Gaku
- Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
-
- Yagura Iori
- Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
-
- Nakamori Shohei
- Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
-
- Matsumura Taishiro
- Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
-
- Yoshioka Takuto
- Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
-
- Kaneko Shizuka
- Department of Diabetes/Endocrinology/Metabolism, Takatsuki Red Cross Hospital, Japan
-
- Kanda Naoki
- Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
Abstract
<p>A 71-year-old woman with recurring stage IV hepatocellular carcinoma (HCC) was admitted to our hospital while being treated with atezolizumab and bevacizumab and complained of fatigue, vomiting, and appetite loss. The following were noted on admission: serum glucose level, 633 mg/dL; metabolic acidemia (HCO3− of 19.5 mmol/L); remarkably low serum and urinary C-peptide levels (0.16 ng/mL and ≤1.5 μg/day, respectively); and urinary ketone body level, 4,197 μmol/L. She was diagnosed with atezolizumab-induced fulminant type 1 diabetes mellitus (T1DM), and insulin therapy improved the symptoms. To our knowledge, this a novel report of atezolizumab-induced fulminant T1DM in an HCC patient. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 62 (12), 1775-1779, 2023-06-15
The Japanese Society of Internal Medicine